Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
Maya N. White, Andrew J. Piper‐Vallillo, Rebecca M. Gardner, Kristen Cunanan, Joel W. Neal, Millie Das, Sukhmani K. Padda, Kavitha Ramchandran, Thomas T. Chen, Lecia V. Sequist, Zofia Piotrowska, Heather A. Wakelee
Topics & Concepts
MedicineOsimertinibChemotherapyBevacizumabOncologyInternal medicineLung cancerHazard ratioImmunotherapyChemotherapy regimenRegimenCancerConfidence intervalErlotinibEpidermal growth factor receptorLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers